About: Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Sector: Healthcare
Industry: Biotechnology
Latest price: $45.08 (+0.67%)
ELVN NASDAQ Enliven Therapeutics Inc.
Enliven Therapeutics Inc. share price
Atividade de preço de ELVN
Último preço
$ 45,080
Variação (24h)
0,30 USD (0,67%)
Volume
907.59K
Volume (média 4 sem.)
-
Abertura
$ 45,29
Variação do dia
$ 44,44 - $ 45,72
Fechamento anterior
$ 44,78
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
ELVN price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals